In A Nutshell Starting aspirin after age 70 did not prevent cancer in a study of nearly 20,000 older adults followed for ...

Low-dose aspirin may limit cancer metastasis by inhibiting platelet activation and enhancing T-cell immunity, supporting biomarker guided use while balancing bleeding risk overall.

A follow-up study suggests that aspirin therapy does not reduce cancer risk in older adults, but may instead increase cancer-related mortality risk.

The use of GLP-1 receptor antagonist therapy has led to a greater reduction in colorectal cancer incidence than has been ...

Longer follow-up of the ASPREE cohort is warranted, says researcher ...

Prior studies, largely among middle-aged adults, have reported that taking aspirin reduces the risk of cancer after 10 years, particularly for colorectal cancer. However, new Monash University ...

Colton Jones, M.D., of The University of Texas San Antonio, discusses aspirin for colorectal cancer prevention after presenting research comparing GLP-1s with aspirin at the 2026 ASCO Gastrointestinal ...

New research by Monash University has found that taking daily low-dose aspirin will not reduce long-term cancer risk in older adults.

Please provide your email address to receive an email when new articles are posted on . Adults who used GLP-1 receptor agonists exhibited a 36% reduction in colorectal cancer risk vs. those who used ...

Prior studies, largely among middle-aged adults, have reported that taking aspirin reduces the risk of cancer after 10 years, particularly for ...

Ozempic and Wegovy might help people avoid colon cancer as well as promote weight loss or control diabetes, a new study says. People who took a GLP-1 drug were 36% less likely to get colon cancer than ...

GLP-1RAs reduced CRC risk by 35.7% compared to aspirin, with greater reductions in high-risk patients and younger individuals. GLP-1RAs showed a favorable safety profile, with lower rates of ...